The wrong medicine in the right box. This Thursday, November 21, the National Agency for Drug Safety (ANSM) and the Arrow Generics laboratory announced the withdrawal from the market of a batch of medications indicated for cholesterol problems. The problem? Another product, prescribed for diabetics, was found for an unspecified reason in a bottle.
“This recall is being carried out as a precautionary measure following the detection of a tablet of Gliclazide 30 mg modified release tablets in a bottleAtorvastatin of this batch”, specifies the ANSM in the withdrawal sheet.
So far only one case of this problem has been reported. This is lot “JBM2300810F”, distributed from February 5, 2024.
“The risk for patients who take gliclazide instead of atorvastatin is hypoglycemia,” specifies the health authority. Thus, they can alert certain signs suggestive of a drop in blood sugar level: sweating, paleness, abnormal feeling of hunger, dizziness, headaches, etc.
“Do not suspend or change your treatment without medical advice”
Instructions are given to people who still have medications from the problem batch in their pantries. “If the reference JBM2300810F appears, do not interrupt or change your treatment without medical advice and return your bottle to the pharmacy,” the Agency asks.
For their part, pharmacists must identify the people to whom they were able to deliver the medication from the batch in question and establish contact. “If a patient brings you a vial of Atorvastatin, verify that it is part of the lot affected by the recall and replace it with a new, compliant vial.”
These incidents are rare but not unprecedented. Last February, BFMTV revealed a recall over a similar story: a hypnotic drug had been discovered in a box of Euphytose, an herbal medicine.
Source: BFM TV
